Alma Karen Orozco-Ochoa

Dr. Alma Karen Orozco-Ochoa

Microbiology, CIAD, Culiacán, Sinaloa, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
JGJean Pierre González-Gómez
Jean Pierre González-Gómez
BQBeatriz Quiñones
Beatriz Quiñones
NCNohelia Castro-Del Campo
Nohelia Castro-Del Campo
JVJosé Benigno Valdez-Torres
José Benigno Valdez-Torres
CCCristóbal Chaidez-Quiroz
Cristóbal Chaidez-Quiroz
Antimicrobial resistance in Acinetobacter baumannii poses a significant global health challenge. Phage therapy, particularly through phage-antibiotic synergy (PAS), offers a promising strategy to combat this pathogen. This study demonstrated significant PAS, where the combination of phage Indie and ceftazidime achieved a bacterial reduction of more than 85% of A. baumannii strain AbAK03 at 17 h using low doses. Notably, this combination overcame phage resistance observed at 4 h when the phage was used alone, extending bacterial eradication by 13 h. Furthermore, phage Indie restored bacterial susceptibility to ceftazidime, supporting its role in improving interventional treatments against multidrug-resistant A. baumannii. To explore this interaction, phage Indie was isolated and characterized from multidrug-resistant clinical strains. An in vitro PAS experiment was performed using ceftazidime and piperacillin-tazobactam. The combination of phage Indie with ceftazidime consistently showed superior bactericidal effects compared to either agent alone, while the combination of phage Indie with piperacillin-tazobactam exhibited an antagonistic effect. These findings provide clear evidence supporting the application of phage-antibiotic combinations as an effective intervention strategy and lay the groundwork for future in vivo trials in a mouse model to combat antimicrobial resistance.

20 October 2022 in Virus Research
Verified
Journal Article
Open access
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
Jean Pierre González-GómezJean Pierre González-Gómez
Jean Pierre González-Gómez
NCNohelia Castro-Del Campo
Nohelia Castro-Del Campo
JLJuan Daniel Lira-Morales
Juan Daniel Lira-Morales
CMCélida Isabel Martínez-Rodríguez
Célida Isabel Martínez-Rodríguez
CCCristóbal Chaidez-Quiroz
Cristóbal Chaidez-Quiroz
• Phages M3, C2, M9, and M83 belong to a new species of the genus of Maculvirus and phages ALK and CHI belong to new genus of the Queuovirinae subfamily. • CHI, ALK, M3, C2, M9, and M83 could lyse 50.0% (5/10) of Mexican AHPND-causing Vibrio parahaemolyticus strains. • No transfer RNA (tRNA), virulence, or antibiotic resistance genes were found in phage genomes. • CHI, ALK, M3, C2, M9, and M83 significantly reduced the growth of Mexican AHPND-causing Vibrio parahaemolyticus strains after incubating with MOI of 0.01–1.

Verified
Journal Article
Open access
PDF file
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
BQBeatriz Quiñones
Beatriz Quiñones
Jean Pierre González-GómezJean Pierre González-Gómez
Jean Pierre González-Gómez
NCNohelia Castro-del Campo
Nohelia Castro-del Campo
JVJosé B. Valdez-Torres
José B. Valdez-Torres
CCCristóbal Chaidez-Quiroz
Cristóbal Chaidez-Quiroz
Acinetobacter baumannii is an opportunistic pathogen and a major cause of nosocomial infections worldwide. This study aimed to isolate and characterize phages with lytic activity against multidrug-resistant A. baumannii strains to enable antibacterial alternatives. Eight phages (AKO8a, PS118, B612, MCR, IDQ7, 89P13, CRL20, and CIM23) were isolated and subjected to genomic, phylogenetic, and functional analyses. Antibacterial activity was assessed in vitro against A. baumannii strain AbAK04 by measuring optical density over 17 h at multiplicities of infection (MOIs) of 0.1, 1, and 10, using a repeated-measures design with time as a crossed factor and MOI as a nested factor. Tukey’s post-hoc test identified significant bacterial growth reductions of 57–72% (p < 0.001). Specifically, phages PS118 and 89P13 reduced growth by 71% at MOI 10; CIM23, B612, and CRL20 achieved 68% reduction at MOI 1; and MCR reduced growth by 64% at MOIs 0.1 and 1. Notably, lytic phage MCR encodes a glycosyl hydrolase family 58 (GH58) enzyme, potentially contributing to its antibacterial activity. Genomic analyses confirmed absence of virulence and antibiotic resistance genes, with all phages classified as novel species within the Kagunavirus genus. These findings support the use of these phages as promising candidates for in vivo evaluation.

2 February 2026 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
BQBeatriz Quiñones
Beatriz Quiñones
BLBertram G Lee
Bertram G Lee
Jean Pierre González-GómezJean Pierre González-Gómez
Jean Pierre González-Gómez
JLJuan Daniel Lira-Morales
Juan Daniel Lira-Morales
CCCristóbal Chaidez-Quiroz
Cristóbal Chaidez-Quiroz

21 January 2024
Verified
Book Chapter
Closed access
LJLuis Alfonso Jiménez-Ortega
Luis Alfonso Jiménez-Ortega
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
OVOctavio Valdez-Baro
Octavio Valdez-Baro
JHJ. Basilio Heredia
J. Basilio Heredia

6 March 2024
Verified
Book Chapter
Closed access
Alma Karen Orozco-OchoaAlma Karen Orozco-Ochoa
Alma Karen Orozco-Ochoa
JGJ.P. González-Gómez
J.P. González-Gómez
AOA.K. Orozco-Ochoa
A.K. Orozco-Ochoa
CSC.C. Sánchez-Armenta
C.C. Sánchez-Armenta